Page last updated: 2024-11-04

adtn

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

ADTN: RN given refers to parent cpd without isomeric designation; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

6-aminohexanoic acid cyclic dimer: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID3153
CHEMBL ID26736
SCHEMBL ID3126243
MeSH IDM0058108
PubMed CID11957526
CHEMBL ID1255656
SCHEMBL ID3763048
MeSH IDM0058108
PubMed CID16
CHEBI ID16968
CHEBI ID133923
MeSH IDM0058108

Synonyms (147)

Synonym
(+)-adtn
gtpl932
(+)-adtn (aminotetralin-6,7-diol)
adtn
LOPAC0_000415
BPBIO1_001127
CMAP_000069
PDSP2_000807
PDSP2_000476
PDSP1_000820
PDSP1_000478
NCGC00162147-02
NCGC00162147-03
6,7-dihydroxy-3-chromanamine
2-amino-6,7-dihydroxytetralin
6,7-dihydroxy-2-aminotetralin
2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene
6-amino-5,6,7,8-tetrahydro-2,3-naphthalenediol
2,3-naphthalenediol, 6-amino-5,6,7,8-tetrahydro-
KBIOSS_002519
KBIO3_002989
KBIOGR_002511
KBIO2_007647
KBIO2_002511
KBIO2_005079
BIOMOL-NT_000003
BSPBIO_001023
NCGC00162147-01
NCGC00162147-04
HMS1990C05
NCGC00015291-06
CHEMBL26736 ,
6-amino-5,6,7,8-tetrahydronaphthalene-2,3-diol
L000081
HMS1792C05
53463-78-8
CCG-204507
ztm7uyi7vx ,
unii-ztm7uyi7vx
AKOS006328808
SR-01000075362-6
NCGC00015291-02
NCGC00015291-03
NCGC00015291-04
NCGC00015291-05
2-aminotetralin-6,7-diol
FT-0645288
SCHEMBL3126243
cid_11957526
bdbm81195
6-amino-5,6,7,8-tetrahydro-naphthalene-2,3-diol
cid_3153
6-azanyl-5,6,7,8-tetrahydronaphthalene-2,3-diol;hydrobromide
2-aminotetralin-6,7-diol;hydrobromide
HMS3403C05
adtn, (+/-)-
(+/-)-6,7-dihydroxy-2-aminotetralin
(+/-)-2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene
2-amino-6,7-dihydroxytetralin, (+/-)-
(+/-)-2-amino-6,7-dihydroxytetralin
Q27074318
SDCCGSBI-0050400.P002
NCGC00015291-07
DTXSID40968175
(+/-)-adtn
smr001254097
MLS002172466 ,
(+/-)-2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene hydrobromide
EU-0100415 ,
nsc287353
nsc-287353
6,7-adtn hydrobromide
13575-86-5
6,7-adtn
NCGC00093839-01
( inverted question mark)-2-amino-6,7-dihydroxy-1,2,3,4-tetrahydro-naphthalene hydrobromide
D-002
SCHEMBL3763048
CHEMBL1255656
sr-01000075362
FT-0641453
73304-33-3
LP00415
CCG-221719
tox21_500415
NCGC00261100-01
adtn, 6,7-
6-amino-5,6,7,8-tetrahydro-naphthalene-2,3-diol hydrobromide
6-amino-5,6,7,8-tetrahydronaphthalene-2,3-diol;hydrobromide
(+/-)-2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene hbr
unii-u1p469341b
2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene hydrobromide
(+/-)-adtn hydrobromide
adtn hydrobromide, (+/-)-
6-amino-5,6,7,8-tetrahydro-2,3-naphthalenediol hydrobromide
u1p469341b ,
2,3-naphthalenediol, 6-amino-5,6,7,8-tetrahydro-, hydrobromide (1:1)
2-amino-6,7-dihydroxytetralin hydrobromide, (+/-)-
AKOS027383301
(??)-2-amino-6,7-dihydroxy-1,2,3,4-tetrahydronaphthalene (hydrobromide)
J-006771
SR-01000075362-1
2,3-naphthalenediol,6-amino-5,6,7,8-tetrahydro-,hydrobromide(1:1)
FT-0708038
DTXSID501017128
(6,7-dihydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)azanium;bromide
6-amino-5,6,7,8-tetrahydronaphthalene-2,3-diol hydrobromide
6,7-dihydroxy-2-aminotetraline hbr
(+/-)-2-amino-6,7-dihydroxytetralin hydrobromide
Q27290569
6,7-adtn hbr
PD015387
E98623
adtn (hydrobromide)
HY-121650A
CS-0169687
CHEBI:16968
6-aminohexanoic acid cyclic dimer
nylon 6 cyclic dimer
6-aminohexanoate cyclic dimer
nylon cyclic dimer
C04277
1,8-diazacyclotetradecane-2,9-dione
CHEBI:133923
56403-09-9
bdbm81871
nsc_16
adtn, (+)
cas_16
lij968e05s ,
7,14-diazacyclotetradecane-1,8-dione
unii-lij968e05s
AKOS016027661
1,8-diaza-2,9-diketocyclotetradecane
caprolactam cyclic dimer
.epsilon.-aminocaproic acid cyclic dimer
cyclic dimer of .epsilon.-caprolactam
2h-azepin-2-one, hexahydro-, cyclic dimer
1,8-diaza-2,9-dioxocyclotetradecane
C20990
HERSSAVMHCMYSQ-UHFFFAOYSA-N
DTXSID90204974
Q27102157
6-aminohexanoate cyclic dimer; 1,8-diaza-2,9-diketocyclotetradecane; (1,8-diazacyclotetradecane-2,9-dione)
6-aminohexanoic acid cyclized dimer
cyclic dimer of caprolactam
1,8-diaza-2,9-dioxo-cyclo-tetradecan

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" The dose-response curve for dopamine-induced relaxation was shifted to the right by the dopamine receptor antagonist d-butaclamol (10(-7)--3 X 10(-6) M) in a concentration-dependent manner."( Stereospecific antagonism by d-butaclamol of dopamine-induced relaxation of the isolated rabbit mesenteric artery.
Brodde, OE; Freistühler, J; Meyer, FJ,
)
0.13
" Analogues 3-6 and 8 exhibited dose-response curves that were bell-shaped in nature with the maximum effect occurring at a concentration of 1 microM."( Synthesis and dopamine receptor modulating activity of lactam conformationally constrained analogues of Pro-Leu-Gly-NH2.
Johnson, RL; Mishra, RK; Sreenivasan, U, 1993
)
0.29
" Like PLG the dose-response curves for 3 and 4 were bell-shaped in nature with the maximum effect occurring at a concentration of 1 microM."( Bicyclic thiazolidine lactam peptidomimetics of the dopamine receptor modulating peptide Pro-Leu-Gly-NH2.
Bontems, RJ; Johnson, RL; McIntee, E; Mishra, RK; Subasinghe, NL, 1993
)
0.29
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
ketoneA compound in which a carbonyl group is bonded to two carbon atoms: R2C=O (neither R may be H).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
nylon-6 oligomer degradation115

Protein Targets (39)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
dopamine D1 receptorHomo sapiens (human)Potency0.01640.00521.30228.1995AID624455
thioredoxin reductaseRattus norvegicus (Norway rat)Potency7.01830.100020.879379.4328AID488773; AID588453
phosphopantetheinyl transferaseBacillus subtilisPotency48.02240.141337.9142100.0000AID1490
GLS proteinHomo sapiens (human)Potency0.63100.35487.935539.8107AID624146
TDP1 proteinHomo sapiens (human)Potency17.92380.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency9.79900.180013.557439.8107AID1460; AID1468
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency23.87700.011212.4002100.0000AID1030
hypothetical protein, conservedTrypanosoma bruceiPotency23.93410.223911.245135.4813AID624147
regulator of G-protein signaling 4Homo sapiens (human)Potency0.07520.531815.435837.6858AID504845
arylsulfatase AHomo sapiens (human)Potency1.06911.069113.955137.9330AID720538
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency1.50030.035520.977089.1251AID504332
D(1A) dopamine receptorHomo sapiens (human)Potency0.09980.02245.944922.3872AID488981; AID488982; AID488983
chromobox protein homolog 1Homo sapiens (human)Potency56.23410.006026.168889.1251AID488953
flap endonuclease 1Homo sapiens (human)Potency1.19170.133725.412989.1251AID488816; AID588795
ubiquitin carboxyl-terminal hydrolase 2 isoform aHomo sapiens (human)Potency1.16680.65619.452025.1189AID463106
M-phase phosphoprotein 8Homo sapiens (human)Potency37.68580.177824.735279.4328AID488949
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency0.53580.060110.745337.9330AID485368
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency0.00250.003245.467312,589.2998AID2517
Chain A, Beta-lactamaseEscherichia coli K-12Potency0.63100.044717.8581100.0000AID485294
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency11.22020.631035.7641100.0000AID504339
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency22.38720.177814.390939.8107AID2147
thioredoxin reductaseRattus norvegicus (Norway rat)Potency29.93490.100020.879379.4328AID588453
GLS proteinHomo sapiens (human)Potency35.48130.35487.935539.8107AID624170
TDP1 proteinHomo sapiens (human)Potency16.79580.000811.382244.6684AID686978; AID686979
Microtubule-associated protein tauHomo sapiens (human)Potency11.22020.180013.557439.8107AID1460
thioredoxin glutathione reductaseSchistosoma mansoniPotency44.66840.100022.9075100.0000AID485364
hypothetical protein, conservedTrypanosoma bruceiPotency26.65140.223911.245135.4813AID624173; AID720584
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency1.00670.035520.977089.1251AID504332
Bloom syndrome protein isoform 1Homo sapiens (human)Potency0.00040.540617.639296.1227AID2364; AID2528
chromobox protein homolog 1Homo sapiens (human)Potency3.98110.006026.168889.1251AID540317
M-phase phosphoprotein 8Homo sapiens (human)Potency79.43280.177824.735279.4328AID488949
D(3) dopamine receptor isoform eHomo sapiens (human)Potency0.02240.02009.148539.8107AID720506
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency4.03890.060110.745337.9330AID485367; AID504636; AID504637
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Carbonic anhydrase 1Homo sapiens (human)Ki14.23000.00001.372610.0000AID1803082
Carbonic anhydrase 2Homo sapiens (human)Ki14.23000.00000.72369.9200AID1803082
D(2) dopamine receptorHomo sapiens (human)IC50 (µMol)0.00000.00000.74728.0000AID62635
DRattus norvegicus (Norway rat)IC50 (µMol)0.00240.00030.50267.7625AID196428; AID196429
D(3) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.00240.00030.39075.4000AID196428; AID196429
D(2) dopamine receptorBos taurus (cattle)IC50 (µMol)0.00600.00100.79948.0000AID62435
Carbonic anhydrase 6Homo sapiens (human)Ki14.23000.00011.47109.9200AID1803082
D(1B) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.00240.00030.35635.4000AID196428; AID196429
D(4) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.00240.00030.38715.4000AID196428; AID196429
D(2) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.23490.00010.54948.4000AID196428; AID196429; AID64451
DBos taurus (cattle)IC50 (µMol)0.00600.00100.47208.0000AID62435
glucose-6-phosphate dehydrogenase-6-phosphogluconolactonasePlasmodium bergheiIC50 (µMol)29.56670.889021.028671.5000AID504765; AID540252; AID540269
glucose-6-phosphate 1-dehydrogenase isoform bHomo sapiens (human)IC50 (µMol)80.00008.870012.851817.8000AID504792
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
mu-type opioid receptor isoform MOR-1Homo sapiens (human)EC50 (µMol)92.47000.13203.30049.5690AID720642
5-hydroxytryptamine receptor 2AMus musculus (house mouse)EC50 (µMol)76.08300.00381.36218.3930AID720643
mu-type opioid receptor isoform MOR-1Homo sapiens (human)EC50 (µMol)92.54400.13203.30049.5690AID624499
5-hydroxytryptamine receptor 2AMus musculus (house mouse)EC50 (µMol)0.01310.00381.36218.3930AID624503
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DRattus norvegicus (Norway rat)ED502.70002.70002.70002.7000AID61013
D(2) dopamine receptorBos taurus (cattle)K Bind0.21000.21000.21000.2100AID62188
D(2) dopamine receptorBos taurus (cattle)Kb0.21000.21000.21000.2100AID62187
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (115)

Processvia Protein(s)Taxonomy
one-carbon metabolic processCarbonic anhydrase 1Homo sapiens (human)
morphogenesis of an epitheliumCarbonic anhydrase 2Homo sapiens (human)
positive regulation of synaptic transmission, GABAergicCarbonic anhydrase 2Homo sapiens (human)
positive regulation of cellular pH reductionCarbonic anhydrase 2Homo sapiens (human)
angiotensin-activated signaling pathwayCarbonic anhydrase 2Homo sapiens (human)
regulation of monoatomic anion transportCarbonic anhydrase 2Homo sapiens (human)
secretionCarbonic anhydrase 2Homo sapiens (human)
regulation of intracellular pHCarbonic anhydrase 2Homo sapiens (human)
neuron cellular homeostasisCarbonic anhydrase 2Homo sapiens (human)
positive regulation of dipeptide transmembrane transportCarbonic anhydrase 2Homo sapiens (human)
regulation of chloride transportCarbonic anhydrase 2Homo sapiens (human)
carbon dioxide transportCarbonic anhydrase 2Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 2Homo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
temperature homeostasisD(2) dopamine receptorHomo sapiens (human)
response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein phosphorylationD(2) dopamine receptorHomo sapiens (human)
response to amphetamineD(2) dopamine receptorHomo sapiens (human)
nervous system process involved in regulation of systemic arterial blood pressureD(2) dopamine receptorHomo sapiens (human)
regulation of heart rateD(2) dopamine receptorHomo sapiens (human)
regulation of sodium ion transportD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(2) dopamine receptorHomo sapiens (human)
positive regulation of neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
positive regulation of receptor internalizationD(2) dopamine receptorHomo sapiens (human)
autophagyD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
neuron-neuron synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
axonogenesisD(2) dopamine receptorHomo sapiens (human)
synapse assemblyD(2) dopamine receptorHomo sapiens (human)
sensory perception of smellD(2) dopamine receptorHomo sapiens (human)
long-term memoryD(2) dopamine receptorHomo sapiens (human)
grooming behaviorD(2) dopamine receptorHomo sapiens (human)
locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
adult walking behaviorD(2) dopamine receptorHomo sapiens (human)
protein localizationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell population proliferationD(2) dopamine receptorHomo sapiens (human)
associative learningD(2) dopamine receptorHomo sapiens (human)
visual learningD(2) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(2) dopamine receptorHomo sapiens (human)
response to light stimulusD(2) dopamine receptorHomo sapiens (human)
response to toxic substanceD(2) dopamine receptorHomo sapiens (human)
response to iron ionD(2) dopamine receptorHomo sapiens (human)
response to inactivityD(2) dopamine receptorHomo sapiens (human)
Wnt signaling pathwayD(2) dopamine receptorHomo sapiens (human)
striatum developmentD(2) dopamine receptorHomo sapiens (human)
orbitofrontal cortex developmentD(2) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(2) dopamine receptorHomo sapiens (human)
adenohypophysis developmentD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell migrationD(2) dopamine receptorHomo sapiens (human)
peristalsisD(2) dopamine receptorHomo sapiens (human)
auditory behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of synaptic transmission, GABAergicD(2) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(2) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
response to histamineD(2) dopamine receptorHomo sapiens (human)
response to nicotineD(2) dopamine receptorHomo sapiens (human)
positive regulation of urine volumeD(2) dopamine receptorHomo sapiens (human)
positive regulation of renal sodium excretionD(2) dopamine receptorHomo sapiens (human)
positive regulation of multicellular organism growthD(2) dopamine receptorHomo sapiens (human)
response to cocaineD(2) dopamine receptorHomo sapiens (human)
negative regulation of circadian sleep/wake cycle, sleepD(2) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(2) dopamine receptorHomo sapiens (human)
drinking behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(2) dopamine receptorHomo sapiens (human)
response to morphineD(2) dopamine receptorHomo sapiens (human)
pigmentationD(2) dopamine receptorHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
positive regulation of G protein-coupled receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(2) dopamine receptorHomo sapiens (human)
negative regulation of innate immune responseD(2) dopamine receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IID(2) dopamine receptorHomo sapiens (human)
negative regulation of insulin secretionD(2) dopamine receptorHomo sapiens (human)
acid secretionD(2) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(2) dopamine receptorHomo sapiens (human)
behavioral response to ethanolD(2) dopamine receptorHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityD(2) dopamine receptorHomo sapiens (human)
response to axon injuryD(2) dopamine receptorHomo sapiens (human)
branching morphogenesis of a nerveD(2) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(2) dopamine receptorHomo sapiens (human)
epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(2) dopamine receptorHomo sapiens (human)
release of sequestered calcium ion into cytosolD(2) dopamine receptorHomo sapiens (human)
dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of synapse structural plasticityD(2) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(2) dopamine receptorHomo sapiens (human)
excitatory postsynaptic potentialD(2) dopamine receptorHomo sapiens (human)
positive regulation of growth hormone secretionD(2) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeD(2) dopamine receptorHomo sapiens (human)
regulation of locomotion involved in locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
negative regulation of cellular response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
positive regulation of glial cell-derived neurotrophic factor productionD(2) dopamine receptorHomo sapiens (human)
positive regulation of long-term synaptic potentiationD(2) dopamine receptorHomo sapiens (human)
hyaloid vascular plexus regressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of neuron migrationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(2) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(2) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(2) dopamine receptorBos taurus (cattle)
negative regulation of prolactin secretionD(2) dopamine receptorBos taurus (cattle)
negative regulation of lactationD(2) dopamine receptorBos taurus (cattle)
positive regulation of mammary gland involutionD(2) dopamine receptorBos taurus (cattle)
hyaloid vascular plexus regressionD(2) dopamine receptorBos taurus (cattle)
detection of chemical stimulus involved in sensory perception of bitter tasteCarbonic anhydrase 6Homo sapiens (human)
one-carbon metabolic processCarbonic anhydrase 6Homo sapiens (human)
synaptic transmission, dopaminergicDBos taurus (cattle)
vasodilationDBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (14)

Processvia Protein(s)Taxonomy
arylesterase activityCarbonic anhydrase 1Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 1Homo sapiens (human)
protein bindingCarbonic anhydrase 1Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 1Homo sapiens (human)
hydro-lyase activityCarbonic anhydrase 1Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 1Homo sapiens (human)
arylesterase activityCarbonic anhydrase 2Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 2Homo sapiens (human)
protein bindingCarbonic anhydrase 2Homo sapiens (human)
zinc ion bindingCarbonic anhydrase 2Homo sapiens (human)
cyanamide hydratase activityCarbonic anhydrase 2Homo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(2) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(2) dopamine receptorHomo sapiens (human)
protein bindingD(2) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(2) dopamine receptorHomo sapiens (human)
dopamine bindingD(2) dopamine receptorHomo sapiens (human)
ionotropic glutamate receptor bindingD(2) dopamine receptorHomo sapiens (human)
identical protein bindingD(2) dopamine receptorHomo sapiens (human)
heterocyclic compound bindingD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(2) dopamine receptorHomo sapiens (human)
zinc ion bindingCarbonic anhydrase 6Homo sapiens (human)
carbonate dehydratase activityCarbonic anhydrase 6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (29)

Processvia Protein(s)Taxonomy
cytosolCarbonic anhydrase 1Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 1Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
cytosolCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
myelin sheathCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 2Homo sapiens (human)
cytoplasmCarbonic anhydrase 2Homo sapiens (human)
plasma membraneCarbonic anhydrase 2Homo sapiens (human)
apical part of cellCarbonic anhydrase 2Homo sapiens (human)
Golgi membraneD(2) dopamine receptorHomo sapiens (human)
acrosomal vesicleD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
ciliumD(2) dopamine receptorHomo sapiens (human)
lateral plasma membraneD(2) dopamine receptorHomo sapiens (human)
endocytic vesicleD(2) dopamine receptorHomo sapiens (human)
axonD(2) dopamine receptorHomo sapiens (human)
dendriteD(2) dopamine receptorHomo sapiens (human)
synaptic vesicle membraneD(2) dopamine receptorHomo sapiens (human)
sperm flagellumD(2) dopamine receptorHomo sapiens (human)
dendritic spineD(2) dopamine receptorHomo sapiens (human)
perikaryonD(2) dopamine receptorHomo sapiens (human)
axon terminusD(2) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(2) dopamine receptorHomo sapiens (human)
ciliary membraneD(2) dopamine receptorHomo sapiens (human)
non-motile ciliumD(2) dopamine receptorHomo sapiens (human)
dopaminergic synapseD(2) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(2) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(2) dopamine receptorHomo sapiens (human)
presynaptic membraneD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
Golgi membraneD(2) dopamine receptorBos taurus (cattle)
extracellular regionCarbonic anhydrase 6Homo sapiens (human)
extracellular spaceCarbonic anhydrase 6Homo sapiens (human)
cytosolCarbonic anhydrase 6Homo sapiens (human)
extracellular exosomeCarbonic anhydrase 6Homo sapiens (human)
extracellular spaceCarbonic anhydrase 6Homo sapiens (human)
endoplasmic reticulum membraneDBos taurus (cattle)
dendritic spineDBos taurus (cattle)
ciliary membraneDBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (85)

Assay IDTitleYearJournalArticle
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1136159Agonist activity at Wistar rat cortex dopamine transporter assessed as tritium efflux by measuring [3H]noradrenaline release at 2 uM after 20 mins by liquid scintillation counting analysis relative to total tissue content1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Facile syntheses of potent dopaminergic argonists and their effect on neurotransmitter release.
AID227265Percentage increase in contractile force was determined by the effect of DMI (desmethylimipramine, 1 mg/kg, iv) at 200 ug/kg1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
N-Aralkyl substitution of 2-amino-5,6- and -6,7-dihydroxy-1,2,3,4-tetrahydronaphthalenes. 1. Cardiac and pressor/depressor activities.
AID60584Inotropic potency expressed as 50 percent increase in right ventricular contractile force in dogs1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
N-Aralkyl substitution of 2-amino-5,6- and -6,7-dihydroxy-1,2,3,4-tetrahydronaphthalenes. 1. Cardiac and pressor/depressor activities.
AID76920Compound was tested for relative intrinsic activity in guinea pig isolated atrium right atria1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
N-Aralkyl substitution of 2-amino-5,6- and -6,7-dihydroxy-1,2,3,4-tetrahydronaphthalenes. 1. Cardiac and pressor/depressor activities.
AID179407Concentration required to reduce the specific binding of [3H]NPA by 50% to rat corpus striatum1984Journal of medicinal chemistry, Oct, Volume: 27, Issue:10
6,7-Dihydroxy-3-chromanamine: synthesis and pharmacological activity of an oxygen isostere of the dopamine agonist 6,7-dihydroxy-2-aminotetralin.
AID61354Affinity for Dopamine receptor D1 binding sites was evaluated in a test involving displacement of [3H]- fenoldopam in rat striatum1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Synthesis and dopaminergic activity of some halogenated mono- and dihydroxylated 2-aminotetralins.
AID196429Inhibitory concentration half-maximal displacement of 1.0 nM [3H]NPA specific binding from rat striatal membranes using 10e-5 (+/-)ADTN1982Journal of medicinal chemistry, Apr, Volume: 25, Issue:4
Synthesis and dopaminergic properties of some exo- and endo-2-aminobenzonorbornenes designed as rigid analogue of dopamine.
AID167290Inhibition of the constrictor response to electrical stimulation in rabbit ear artery.1986Journal of medicinal chemistry, May, Volume: 29, Issue:5
Dopamine receptor agonists: 3-allyl-6-chloro-2,3,4,5-tetrahydro- 1-(4-hydroxyphenyl)-1H-3-benzazepine-7,8-diol and a series of related 3-benzazepines.
AID58655Ionotropic selectivity expressed as change in heart rate for 100 percent increase in right ventricular contractile force in dogs1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
N-Aralkyl substitution of 2-amino-5,6- and -6,7-dihydroxy-1,2,3,4-tetrahydronaphthalenes. 1. Cardiac and pressor/depressor activities.
AID1136164Agonist activity at Wistar rat cortex dopamine transporter assessed as tritium efflux by measuring [3H]noradrenaline release at 1 uM after 20 to 30 mins by liquid scintillation counting analysis in presence of nomifensine1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Facile syntheses of potent dopaminergic argonists and their effect on neurotransmitter release.
AID73727Effective concentration for increasing potency rate in guinea pig isolated right atria1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
N-Aralkyl substitution of 2-amino-5,6- and -6,7-dihydroxy-1,2,3,4-tetrahydronaphthalenes. 1. Cardiac and pressor/depressor activities.
AID61013The ability of a compound to stimulate dopamine-sensitive rat caudate adenylate cyclase or to antagonise the stimulant of dopamine was used as measure of D1 efficacy1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Synthesis and dopaminergic activity of some halogenated mono- and dihydroxylated 2-aminotetralins.
AID167471The D2 efficacy was evaluated in isolated perfused rabbit ear artery test1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Synthesis and dopaminergic activity of some halogenated mono- and dihydroxylated 2-aminotetralins.
AID1136158Agonist activity at Wistar rat striatum dopamine transporter assessed as tritium efflux by measuring [3H]dopamine release at 2 uM after 20 mins by liquid scintillation counting analysis relative to total tissue content1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Facile syntheses of potent dopaminergic argonists and their effect on neurotransmitter release.
AID1136162Agonist activity at Wistar rat brain cholinergic transporter assessed as tritium efflux by measuring [3H]choline release at 2 uM after 20 to 30 mins by liquid scintillation counting analysis relative to control1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Facile syntheses of potent dopaminergic argonists and their effect on neurotransmitter release.
AID65751Competitive binding assay against Dopamine receptor D2 in rat striatal membranes and [125I]-IBF radioligand1990Journal of medicinal chemistry, Jan, Volume: 33, Issue:1
Synthesis and characterization of iodobenzamide analogues: potential D-2 dopamine receptor imaging agents.
AID76919Compound was tested for or relative intrinsic activity in guinea pig isolated atrium left atria1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
N-Aralkyl substitution of 2-amino-5,6- and -6,7-dihydroxy-1,2,3,4-tetrahydronaphthalenes. 1. Cardiac and pressor/depressor activities.
AID62861Evaluated for the inhibition of binding of [3H]DA (dopamine) to dopamine receptor in rat brain homogenate1982Journal of medicinal chemistry, Jul, Volume: 25, Issue:7
Synthesis and dopamine receptor binding of exo- and endo-2-amino-6,7-dihydroxybenzonorbornene, rigid analogues of 2-amino-6,7-dihydroxytetrahydronaphthalene.
AID196428Inhibitory concentration for half-maximal displacement of 1.0 nM [3H]ADTN specific binding from rat striatal membranes using 10E-5 sulpiride1982Journal of medicinal chemistry, Apr, Volume: 25, Issue:4
Synthesis and dopaminergic properties of some exo- and endo-2-aminobenzonorbornenes designed as rigid analogue of dopamine.
AID58658Ionotropic selectivity expressed as change in heart rate for 50 percent increase in right ventricular contractile force in dogs1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
N-Aralkyl substitution of 2-amino-5,6- and -6,7-dihydroxy-1,2,3,4-tetrahydronaphthalenes. 1. Cardiac and pressor/depressor activities.
AID60580Inotropic potency expressed as 100 percent increase in right ventricular contractile force in dogs1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
N-Aralkyl substitution of 2-amino-5,6- and -6,7-dihydroxy-1,2,3,4-tetrahydronaphthalenes. 1. Cardiac and pressor/depressor activities.
AID1136160Agonist activity at Wistar rat brain serotonin transporter assessed as tritium efflux by measuring [3H]serotonin release at 2 uM after 20 to 30 mins by liquid scintillation counting analysis relative to control1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Facile syntheses of potent dopaminergic argonists and their effect on neurotransmitter release.
AID25622Evaluated for the pKa value.1982Journal of medicinal chemistry, Jun, Volume: 25, Issue:6
Synthesis of 2-(alkylamino)-5,6- and -6,7-dihydroxy-3,4-dihydroquinazolines and evaluation as potential dopamine agonists.
AID62028The compound was tested for its ability to inhibit specific [3H]spiroperidol binding to bovine anterior pituitary homogenate, at 10 uM; e=Value not determined1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Dopamine receptor agonist activity of some 5-(2-aminoethyl)carbostyril derivatives.
AID24237Partition coefficient (logP)1984Journal of medicinal chemistry, Oct, Volume: 27, Issue:10
6,7-Dihydroxy-3-chromanamine: synthesis and pharmacological activity of an oxygen isostere of the dopamine agonist 6,7-dihydroxy-2-aminotetralin.
AID64451Inhibition of specific binding of [3H]spiroperidol to Dopamine receptor D2 in rat striatal membranes1998Journal of medicinal chemistry, Oct-08, Volume: 41, Issue:21
N-(Iodopropenyl)-octahydrobenzo[f]- and -[g]quinolines: synthesis and adrenergic and dopaminergic activity studies.
AID1136161Agonist activity at Wistar rat brain GABA transporter assessed as tritium efflux by measuring [3H]GABA release at 2 uM after 20 to 30 mins by liquid scintillation counting analysis relative to control1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Facile syntheses of potent dopaminergic argonists and their effect on neurotransmitter release.
AID62435Evaluated for the inhibition of binding of [3H]DA (dopamine) to dopamine receptor in calf striatal homogenate1982Journal of medicinal chemistry, Jul, Volume: 25, Issue:7
Synthesis and dopamine receptor binding of exo- and endo-2-amino-6,7-dihydroxybenzonorbornene, rigid analogues of 2-amino-6,7-dihydroxytetrahydronaphthalene.
AID57843Cardioselectivity expressed as change in blood pressure for 100% increase in right ventricular contractile force in dogs1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
N-Aralkyl substitution of 2-amino-5,6- and -6,7-dihydroxy-1,2,3,4-tetrahydronaphthalenes. 1. Cardiac and pressor/depressor activities.
AID132337Compound concentration that causes inhibition of [3H]-acetyl choline release by 50% was determined using reserpine-alpha MPT treated mice striatal slices1984Journal of medicinal chemistry, May, Volume: 27, Issue:5
Dopaminergic agonists: comparative actions of amine and sulfonium analogues of dopamine.
AID61209Tested for its ability to inhibit rat caudate adenylate cyclase (Dopamine receptor D1) at 10 uM; e=Value not determined1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Dopamine receptor agonist activity of some 5-(2-aminoethyl)carbostyril derivatives.
AID61011Tested for its ability to stimulate rat caudate adenylate cyclase (Dopamine receptor D1) at 10 uM1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Dopamine receptor agonist activity of some 5-(2-aminoethyl)carbostyril derivatives.
AID57846Cardioselectivity expressed as change in blood pressure for 50% increase in right ventricular contractile force in dogs1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
N-Aralkyl substitution of 2-amino-5,6- and -6,7-dihydroxy-1,2,3,4-tetrahydronaphthalenes. 1. Cardiac and pressor/depressor activities.
AID1136163Agonist activity at Wistar rat striatum dopamine transporter assessed as tritium efflux by measuring [3H]dopamine release at 1 uM after 20 to 30 mins by liquid scintillation counting analysis in presence of nomifensine1978Journal of medicinal chemistry, Aug, Volume: 21, Issue:8
Facile syntheses of potent dopaminergic argonists and their effect on neurotransmitter release.
AID73725Effective concentration for increasing potency force in guinea pig isolated left atria1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
N-Aralkyl substitution of 2-amino-5,6- and -6,7-dihydroxy-1,2,3,4-tetrahydronaphthalenes. 1. Cardiac and pressor/depressor activities.
AID167713The compound was tested for DA agonistic activity in the isolated perfused rabbit ear artery.1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Dopamine receptor agonist activity of some 5-(2-aminoethyl)carbostyril derivatives.
AID62635Agonist required to inhibit Dopamine receptor D2 photoinactivation by 50% with Iodazidoclebopride using [3H]-Spiperone1985Journal of medicinal chemistry, Apr, Volume: 28, Issue:4
Novel photoaffinity label for the dopamine D2 receptor: synthesis of 4-azido-5-iodo-2-methoxy-N-[1-(phenylmethyl)-4-piperidinyl] benzamide (iodoazidoclebopride, IAC) and the corresponding 125I-labeled analogue (125IAC).
AID62188Affinity for Dopamine receptor D2 was evaluated from the ability to displace [3H]spiroperidol from homogenized bovine pituitary1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
Synthesis and dopaminergic activity of some halogenated mono- and dihydroxylated 2-aminotetralins.
AID62187The compound was tested for its ability to inhibit specific [3H]spiroperidol binding to bovine anterior pituitary homogenate, at 10 uM1985Journal of medicinal chemistry, Dec, Volume: 28, Issue:12
Dopamine receptor agonist activity of some 5-(2-aminoethyl)carbostyril derivatives.
AID187151Binding affinity to rat corpus striatum was determined using [3H]NPA as radioligand1984Journal of medicinal chemistry, Oct, Volume: 27, Issue:10
6,7-Dihydroxy-3-chromanamine: synthesis and pharmacological activity of an oxygen isostere of the dopamine agonist 6,7-dihydroxy-2-aminotetralin.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1345718Human D1 receptor (Dopamine receptors)1991Nature, Apr-18, Volume: 350, Issue:6319
Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.
AID1345718Human D1 receptor (Dopamine receptors)2002The Journal of pharmacology and experimental therapeutics, Nov, Volume: 303, Issue:2
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.
AID1345879Human D5 receptor (Dopamine receptors)1991Nature, Apr-18, Volume: 350, Issue:6319
Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.
AID1803082CA Activity Assay from Article 10.3109/14756366.2011.591290: \\Effects of dopaminergic compounds on carbonic anhydrase isozymes I, II, and VI.\\2012Journal of enzyme inhibition and medicinal chemistry, Jun, Volume: 27, Issue:3
Effects of dopaminergic compounds on carbonic anhydrase isozymes I, II, and VI.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID524796Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay2009Nature chemical biology, Oct, Volume: 5, Issue:10
Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (171)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990121 (70.76)18.7374
1990's16 (9.36)18.2507
2000's13 (7.60)29.6817
2010's14 (8.19)24.3611
2020's7 (4.09)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 64.90

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index64.90 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.39 (4.65)
Search Engine Demand Index102.15 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (64.90)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Trials0 (0.00%)5.53%
Reviews4 (2.50%)6.00%
Reviews0 (0.00%)6.00%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other156 (97.50%)84.16%
Other9 (100.00%)84.16%
Other6 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]